GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture ... of Horlicks and other consumer healthcare nutrition products to fund the acquisition, after saying last ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis Consumer Health introduced PPA-free ... The categorization will effectively ban use of PPA in OTC products in the United States. Smith acknowledged, however, that PPA might be able ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In 1963, Ciba introduced a breakthrough product for the treatment ... The same year, Novartis acquired the North American over-the-counter brand portfolio of Bristol-Myers Squibb.

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.